547. Molnupiravir and Nirmatrelvir/Ritonavir Effectiveness in Reducing the Risk for COVID-19 Disease Progression and Death

BACKGROUND: Molnupiravir (M) and Nirmatrelvir/Ritonavir (N/R) have been authorized for use in COVID-19 patients at high risk for severe disease. We aimed to evaluate the effectiveness of M and N/R in highly vulnerable SARS-CoV-2 patients using a retrospective cohort study design. METHODS: The study...

Descripción completa

Detalles Bibliográficos
Autores principales: Paraskevis, Dimitrios, Gkova, Mary, Mellou, Kassiani, Gkolfinopoulou, Kassiani, Kostaki, Evangelia Georgia, Loukides, Stylianos, Kotanidou, Anastasia, Skoutelis, Athanasios, Thiraios, Eleftherios, Saroglou, George, Zografopoulos, Dimitrios, Mossialos, Elias, Zaoutis, Theoklis, Gaga, Mina, Antoniadou, Anastasia, Tsiodras, Sotirios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677556/
http://dx.doi.org/10.1093/ofid/ofad500.616

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677556/
http://dx.doi.org/10.1093/ofid/ofad500.616

Ejemplares similares